Sensorion participates in the 33rd ESGCT Congress

The biotechnology company Sensorion announces its presence at the 33rd Annual Congress of the European Society for Gene and Cell Therapy (ESGCT), which takes place in Hamburg, Germany, from October 27 to 30, 2026. Sensorion, specializing in therapies for hearing, will present two posters on its research.

Lise Barrot, a preclinical researcher, will present results on a new gene therapy to treat DFNB1A deafness. This presentation is scheduled for October 28, 2026.

Laurent Desire, head of preclinical development, will present the poster on SENS-601. This treatment targets autosomal recessive 1A non-syndromic deafness, with a presentation scheduled for October 29, 2026.